What is Amphastar Pharmaceuticals Equity-to-Asset?
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Amphastar Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $639.4 Mil. Amphastar Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $1,512.9 Mil.
Therefore, Amphastar Pharmaceuticals's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was 0.42.
The historical rank and industry rank for Amphastar Pharmaceuticals's Equity-to-Asset or its related term are showing as below:
AMPH'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.42 Med: 0.69 Max: 0.77
Current: 0.42
During the past 13 years, the highest Equity to Asset Ratio of Amphastar Pharmaceuticals was 0.77. The lowest was 0.42. And the median was 0.69.
AMPH's Equity-to-Asset is ranked worse than 69.92% of 1087
companies
in the Drug Manufacturers industry
Industry Median: 0.59
vs AMPH: 0.42
Amphastar Pharmaceuticals Equity-to-Asset Historical Data
The historical data trend for Amphastar Pharmaceuticals's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amphastar Pharmaceuticals's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amphastar Pharmaceuticals's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Amphastar Pharmaceuticals's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Amphastar Pharmaceuticals's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Amphastar Pharmaceuticals Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Amphastar Pharmaceuticals's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Amphastar Pharmaceuticals (Amphastar Pharmaceuticals) Business Description
Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AMPH has been successfully added to your 